Claims
- 1. A method for the improvement of lung function, comprising administering to a mammalian subject diagnosed with a disease or condition benefiting from the improvement of lung function an effective amount of a molecule capable of inhibiting a biological activity mediated by a TGFβ-R1 kinase receptor.
- 2. The method of claim 1 wherein said disease or condition benefiting from the improvement of lung function is selected from the group consisting of emphysema, chronic bronchitis, chronic obstructive pulmonary disease (COPD), pulmonary edema, cystic fibrosis, occlusive lung disease, acute respiratory deficiency syndrome (ARDS), asthma, radiation-induced injury of the lung, lung injuries resulting from infectious causes, inhaled toxins, or circulating exogenous toxins, aging and genetic predisposition to impaired lung function.
- 3. The method of claim 1 wherein said disease or condition benefiting from the improvement of lung function involves acute lung injury.
- 4. The method of claim 1 wherein said disease or condition benefiting from the improvement of lung function is unaccompanied by lung fibrosis.
- 5. The method of claim 1 wherein said disease or condition benefiting from the improvement of lung function is at a stage when lung fibrosis is not a major symptom.
- 6. The method of claim 1 wherein said molecule specifically binds to said TGFβ-R1 kinase receptor.
- 7. The method of claim 1 wherein said molecule additionally inhibits a biological activity mediated by p38 kinase.
- 8. The method of claim 1 wherein said molecule preferentially inhibits a biological activity mediated by TGF-β-R1 kinase relative to a biological activity mediated by p38 kinase.
- 9. The method of claim 1 wherein said compound is a non-peptide small molecule.
- 10. The method of claim 9 wherein said compound is a small organic molecule.
- 11. The method of claim 10 wherein said small organic molecule is other than an imidazole derivative.
- 12. The method of claim 10 wherein said molecule is a compound of formula (1)
- 13. The method of claim 12 wherein said compound is a quinazoline derivative.
- 14. The method of claim 13 wherein Z3 is N; and Z1-Z8 are CR2.
- 15. The method of claim 13 wherein Z3 is N; and at least one of Z1-Z8 is nitrogen.
- 16. The method of claim 13 wherein R3 is an optionally substituted phenyl moiety.
- 17. The method of claim 16 wherein R3 is selected from the group consisting of 2-, 4-, 5-, 2,4- and 2,5-substituted phenyl moieties.
- 18. The method of claim 17 wherein at least one substituent of said phenyl moiety is an alkyl(1-6C), or halo.
- 19. The method of claim 10 wherein said small organic molecule is a compound of formula (2)
- 20. The method of claim 10 wherein said small organic molecule is a compound of formula (3)
- 21. The method of claim 10 wherein said small organic molecule is a compound of formula (4)
- 22. A method for the treatment of a subject having impaired lung function comprising administering to said subject an effective amount of a molecule capable of inhibiting a biological activity mediated by a TGFβ-R1 kinase receptor.
- 23. The method of claim 22 wherein said subject is human.
- 24. The method of claim 23 wherein said molecule specifically binds to said TGFβ-R1 kinase receptor.
- 25. The method of claim 24 wherein said impaired lung function is associated with a disease or condition selected from the group consisting of emphysema, chronic bronchitis, chronic obstructive pulmonary disease (COPD), pulmonary edema, cystic fibrosis, occlusive lung disease, acute respiratory deficiency syndrome (ARDS), asthma, radiation-induced injury of the lung, lung injuries resulting from infectious causes, inhaled toxins, or circulating exogenous toxins, aging and genetic predisposition to impaired lung function.
- 26. The method of claim 25 wherein administration is in the form of a pharmaceutical composition.
- 27. The method of claim 26 wherein said pharmaceutical composition is suitable for oral administration.
- 28. The method of claim 26 wherein said pharmaceutical composition is suitable for intravenous administration.
- 29. The method of claim 26 wherein said pharmaceutical composition is suitable for aerosol administration.
- 30. The method of claim 26 wherein said pharmaceutical composition is suitable for intrapulmonary administration.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a non-provisional application filed under 37 CFR 1.53(b), claiming priority under USC Section 119(e) to provisional Application Ser. No. 60/399,368 filed Jul. 25, 2002.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60399369 |
Jul 2002 |
US |
|
60399368 |
Jul 2002 |
US |